Abstract Background Long‐acting injectable cabotegravir and rilpivirine (LAI CAB + RPV) is an established maintenance strategy for people with HIV who are virologically suppressed, providing high efficacy and convenience in treatment. However, evidence in older adults (≥60 years), a growing and complex population, is limited. Methods We conducted an ambispective real‐world sub‐analysis of the Spanish RELATIVITY cohort, including people with HIV aged ≥60 years who initiated LAI CAB + RPV across 58 centres. Outcomes (virological suppression, safety, discontinuation and adherence) were compared with those 89% of the participants aged ≥60 years demonstrating perfect adherence. Conclusion In this large multicentre real‐world sub‐study, LAI CAB + RPV maintained virological control and showed good tolerability in older people with HIV despite high multi‐morbidity and long‐term ART exposure. These findings extend the evidence from previous trials and support LAI CAB + RPV as a feasible option for geriatric HIV care. Longer follow‐up will provide further insights into durability and quality‐of‐life benefits.
Troya et al. (2025) studied this question.